Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Initial Results of a Phase I Trial

E. Bayever, P. L. Iversen, M. R. Bishop, John G Sharp, H. K. Tewary, M. A. Arneson, Samuel Jay Pirruccello, R. W. Ruddon, A. Kessinger, G. Zon, James Olen Armitage

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

A synthetic phosphorothioate oligonucleotide was administered systemically to five patients with either relapsed or refractory acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS). Patients received a 10-day continuous intravenous infusion of this compound, which is complementary to p53 mRNA. No major toxicity attributable to a dose of 0.05 mg/kg/hr was observed. A range of approximately 9 to 18% of the administered dose was recovered in the urine as intact oligonucleotide. Evaluation of malignant cells recovered from bone marrow and peripheral blood at intervals before, during, and after treatment reveals no enhanced growth potential following oligonucleotide administration. Hence, a phosphorothioate oligonucleotide complementary to p53 mRNA can be administered at this dose level to humans without major toxicity. Higher doses need to be evaluated for toxicity and potential clinical efficacy.

Original languageEnglish (US)
Pages (from-to)383-390
Number of pages8
JournalAntisense Research and Development
Volume3
Issue number4
DOIs
StatePublished - Jan 1 1993

Fingerprint

Phosphorothioate Oligonucleotides
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Oligonucleotides
Toxicity
Messenger RNA
Intravenous Infusions
Bone Marrow Cells
Urine
Refractory materials
Bone
Blood
Growth
Therapeutics

ASJC Scopus subject areas

  • Genetics

Cite this

Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome : Initial Results of a Phase I Trial. / Bayever, E.; Iversen, P. L.; Bishop, M. R.; Sharp, John G; Tewary, H. K.; Arneson, M. A.; Pirruccello, Samuel Jay; Ruddon, R. W.; Kessinger, A.; Zon, G.; Armitage, James Olen.

In: Antisense Research and Development, Vol. 3, No. 4, 01.01.1993, p. 383-390.

Research output: Contribution to journalArticle

@article{0f483ca781f54efc8c8f5241772fa189,
title = "Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial",
abstract = "A synthetic phosphorothioate oligonucleotide was administered systemically to five patients with either relapsed or refractory acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS). Patients received a 10-day continuous intravenous infusion of this compound, which is complementary to p53 mRNA. No major toxicity attributable to a dose of 0.05 mg/kg/hr was observed. A range of approximately 9 to 18{\%} of the administered dose was recovered in the urine as intact oligonucleotide. Evaluation of malignant cells recovered from bone marrow and peripheral blood at intervals before, during, and after treatment reveals no enhanced growth potential following oligonucleotide administration. Hence, a phosphorothioate oligonucleotide complementary to p53 mRNA can be administered at this dose level to humans without major toxicity. Higher doses need to be evaluated for toxicity and potential clinical efficacy.",
author = "E. Bayever and Iversen, {P. L.} and Bishop, {M. R.} and Sharp, {John G} and Tewary, {H. K.} and Arneson, {M. A.} and Pirruccello, {Samuel Jay} and Ruddon, {R. W.} and A. Kessinger and G. Zon and Armitage, {James Olen}",
year = "1993",
month = "1",
day = "1",
doi = "10.1089/ard.1993.3.383",
language = "English (US)",
volume = "3",
pages = "383--390",
journal = "Nucleic Acid Therapeutics",
issn = "2159-3337",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

T2 - Initial Results of a Phase I Trial

AU - Bayever, E.

AU - Iversen, P. L.

AU - Bishop, M. R.

AU - Sharp, John G

AU - Tewary, H. K.

AU - Arneson, M. A.

AU - Pirruccello, Samuel Jay

AU - Ruddon, R. W.

AU - Kessinger, A.

AU - Zon, G.

AU - Armitage, James Olen

PY - 1993/1/1

Y1 - 1993/1/1

N2 - A synthetic phosphorothioate oligonucleotide was administered systemically to five patients with either relapsed or refractory acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS). Patients received a 10-day continuous intravenous infusion of this compound, which is complementary to p53 mRNA. No major toxicity attributable to a dose of 0.05 mg/kg/hr was observed. A range of approximately 9 to 18% of the administered dose was recovered in the urine as intact oligonucleotide. Evaluation of malignant cells recovered from bone marrow and peripheral blood at intervals before, during, and after treatment reveals no enhanced growth potential following oligonucleotide administration. Hence, a phosphorothioate oligonucleotide complementary to p53 mRNA can be administered at this dose level to humans without major toxicity. Higher doses need to be evaluated for toxicity and potential clinical efficacy.

AB - A synthetic phosphorothioate oligonucleotide was administered systemically to five patients with either relapsed or refractory acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS). Patients received a 10-day continuous intravenous infusion of this compound, which is complementary to p53 mRNA. No major toxicity attributable to a dose of 0.05 mg/kg/hr was observed. A range of approximately 9 to 18% of the administered dose was recovered in the urine as intact oligonucleotide. Evaluation of malignant cells recovered from bone marrow and peripheral blood at intervals before, during, and after treatment reveals no enhanced growth potential following oligonucleotide administration. Hence, a phosphorothioate oligonucleotide complementary to p53 mRNA can be administered at this dose level to humans without major toxicity. Higher doses need to be evaluated for toxicity and potential clinical efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0027729703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027729703&partnerID=8YFLogxK

U2 - 10.1089/ard.1993.3.383

DO - 10.1089/ard.1993.3.383

M3 - Article

VL - 3

SP - 383

EP - 390

JO - Nucleic Acid Therapeutics

JF - Nucleic Acid Therapeutics

SN - 2159-3337

IS - 4

ER -